Skip to main content
. Author manuscript; available in PMC: 2021 Sep 2.
Published in final edited form as: Hepatology. 2020 Sep 2;72(3):1085–1101. doi: 10.1002/hep.31096

Figure 8. Effect of regorafenib and sorafenib on angiogenesis and cell proliferation in PDX models.

Figure 8.

A. Representative images of H&E, angiogenesis (CD31), and proliferation (Ki-67) of HCC-HS84 PDX treated with Sorafenib or Regorafenib (left). Statistical analysis of CD31 positive area and Ki-67 positive cells (right). Scale bar = 100μm.

B. Representative images of H&E, angiogenesis (CD31) and proliferation (Ki-67) of HCC-HS157 PDX treated with Sorafenib or Regorafenib (left). Statistical analysis of CD31 positive area and Ki-67 positive cells (right). Scale bar = 100μm.